Literature DB >> 19398113

The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.

S G Schorr1, C J Slooff, R Bruggeman, K Taxis.   

Abstract

Cross-sectional studies showed a high prevalence of metabolic syndrome in patients with schizophrenia.This study aimed to identify the incidence of metabolic syndrome and its reversal in a non-preselected cohort of chronic psychotic patients in routine practice in one year follow-up and to find variables to describe development and reversal of metabolic syndrome. This cohort study was conducted as part of a disease management program and patients were included if they had two complete assessments in a one year follow-up. We conducted two logistic regressions to find variables to describe the development of metabolic syndrome and the reversal of metabolic syndrome. At the time of the first assessment 35% (n=92) of the 260 included patients had metabolic syndrome. Within one year 21 patients developed metabolic syndrome and 30 patients had it reversed. This was an incidence of 13% (21/168) and a reversal of 33% (30/92). Smoking, family history of cardiovascular diseases, and duration of disease >6 years was associated with a higher risk of developing metabolic syndrome as well as abdominal obesity and dyslipidemia. Patients with abdominal obesity had a smaller chance of reversing metabolic syndrome. Other variables included in the logistic regression such as receiving cardiovascular/antidiabetic drug treatment or duration of disease >6 years did not alter the risk of reversing the metabolic syndrome. Our study showed that the natural course of metabolic syndrome is dynamic. A considerable number of patients developed or reversed the metabolic syndrome in one year follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19398113     DOI: 10.1016/j.jpsychires.2009.03.002

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  13 in total

1.  Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness.

Authors:  Joseph C Ratliff; Laura B Palmese; Erin L Reutenauer; Vinod H Srihari; Cenk Tek
Journal:  Psychosomatics       Date:  2012-06-02       Impact factor: 2.386

2.  Antioxidant effects of rice bran oil mitigate repeated haloperidol-induced tardive dyskinesia in male rats.

Authors:  Noreen Samad; Darakhshan Jabeen Haleem
Journal:  Metab Brain Dis       Date:  2017-04-03       Impact factor: 3.584

3.  Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.

Authors:  Marc De Hert; Aurélia Mittoux; Yuan He; Joseph Peuskens
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-05       Impact factor: 5.270

Review 4.  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.

Authors:  Christine Rummel-Kluge; Katja Komossa; Sandra Schwarz; Heike Hunger; Franziska Schmid; Claudia Asenjo Lobos; Werner Kissling; John M Davis; Stefan Leucht
Journal:  Schizophr Res       Date:  2010-08-07       Impact factor: 4.939

5.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 6.  Cardiometabolic effects of psychotropic medications.

Authors:  Oluchi Abosi; Sneha Lopes; Samantha Schmitz; Jess G Fiedorowicz
Journal:  Horm Mol Biol Clin Investig       Date:  2018-01-10

7.  Area-level socioeconomic characteristics and incidence of metabolic syndrome: a prospective cohort study.

Authors:  Anh D Ngo; Catherine Paquet; Natasha J Howard; Neil T Coffee; Robert Adams; Anne Taylor; Mark Daniel
Journal:  BMC Public Health       Date:  2013-07-25       Impact factor: 3.295

8.  Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia.

Authors:  Junji Saruwatari; Norio Yasui-Furukori; Ryoko Kamihashi; Yuki Yoshimori; Kentaro Oniki; Shoko Tsuchimine; Madoka Noai; Yasushi Sato; Taku Nakagami; Norio Sugawara; Manabu Saito; Akira Fujii; Ayami Kajiwara; Shuichi Mihara; Yasuhiro Ogata; Sunao Kaneko; Kazuko Nakagawa
Journal:  Neuropsychiatr Dis Treat       Date:  2013-11-01       Impact factor: 2.570

9.  Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study.

Authors:  Jung Sun Lee; Jun Soo Kwon; Daeho Kim; Sung-Wan Kim; Jae-Jin Kim; Jong-Hoon Kim; Hee Jung Nam; Seunghyong Ryu; Il Ho Park; Suk Kyoon An; Hong-Seok Oh; Seunghee Won; Kanguk Lee; Kyu Young Lee; Seung-Hwan Lee; Yu Sang Lee; Jung-Seo Yi; Kyung Sue Hong; Yeon Ho Joo
Journal:  Psychiatry Investig       Date:  2016-12-29       Impact factor: 2.505

Review 10.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.